Obtain a Get Started Pack Today!

Oncology Practice Advisor

Brought to you by Myriad Genetic Laboratories, Inc.

Educating Providers on Hereditary Cancer

“Family history is key to the identification of those individuals who have an inherited predisposition to malignancy or who are at increased risk for additional primary cancers.”

– Journal of Clinical Oncology, Feb. 3, 2014, Lu, et al (1)

Understanding a patient’s personal and family cancer history is essential for providing high quality, precision care in oncology and gynecologic oncology practices. Physicians and nurses have an important role in identifying patients and families with hereditary cancer risks and helping to prevent cancers that are likely to occur.

As a global leader in molecular diagnostics, Myriad Genetic Laboratories is committed to educating providers on hereditary cancer, medical information and resources to help you stay informed on the rapidly evolving world of cancer genetics.

"Despite the importance of family history in cancer risk assessment, studies have shown that physicians do not always take and/or update a family history and that there is a lack of completeness of the documented family history."

– Journal of Clinical Oncology, Feb. 3, 2014, Wood, et al. (2)

In this online oncology practice advisory program, you will learn about:

1.Hereditary Cancer
General cancer genetics

2.Patient Impact
The impact on patients

3.Process
Steps to identify hereditary cancer risk

4.Test Accuracy Importance
Importance of test accuracy

Myriad, the Myriad logo, MyriadPro, the MyriadPro logo, Myriad myRisk Hereditary Cancer, the Myriad myRisk Hereditary Cancer logo, Myriad myPath Melanoma, the Myriad myPath Melanoma logo, Myriad myPlan Lung Cancer, the Myriad myPlan Lung Cancer logo, BRACAnalysis, the BRACAnalysis logo, COLARIS, the COLARIS logo, COLARIS AP, the COLARIS AP logo, MELARIS, the MELARIS logo, PANEXIA, the PANEXIA logo, Prolaris, the Prolaris logo, ResultsNow, the ResultsNow logo, Myriad Promise, and the Myriad Promise logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.

Copyright © 2015 Myriad Genetic Laboratories all rights reserved

Next Section:
Hereditary Cancer

References

  1. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Lancet. 1994;343(8899):692-695.
  2. The Breast Cancer Linkage Consortium. Cancer Risks in BRCA2 Mutation Carriers. J Natl Cancer Inst. 1999;91(15):1310-1316.
  3. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22(12):2328-2335.
  4. Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999;8(10):855-861.
  5. Metcalfe KA, Lynch HT, Ghadirian P, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005;96(1):222-226.